Eaton Vance Tax Advantaged Dividend (EVT) 19.68 $EVT
Eaton Vance Closed-End Equity Funds Declare Monthly Distributions
PR Newswire - Fri Apr 11, 2:13PM CDT
Eaton Vance Management, the Boston-based investment adviser, announced the monthly distributions declared on the common shares of two of its closed-end equity funds (the "Funds"
. As portfolio and market conditions change, the rate of future distributions may change. The record date for the distributions is April 23, 2014, and the payable date is April 30, 2014. The ex-date is April 21, 2014. The distribution per share for each Fund is as follows:
Evotec and Convergence Form Integrated Pain Alliance
GlobeNewswire - Mon Mar 31, 12:40AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain. Panion Ltd has been awarded a £ 2.4 m Technology Strategy Board Biomedical Catalyst Early Stage Round 2 grant to discover and develop compounds against a novel GPCR pain target. Evotec will be responsible for undertaking key drug discovery activities and will work closely with the Convergence team in identifying pre-clinical candidates over the next three years. Subsequently, and upon meeting certain pre-clinical milestones, Convergence and Evotec will jointly progress the assets further into the clinic or via partnering. Further financials remain undisclosed.
Evotec FY 2013: Execute on Innovate to Create Value
GlobeNewswire - Tue Mar 25, 1:59AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISINE0005664809) today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013.
Evotec AG: Fiscal Year 2013 Results Presentation on 25 March 2014
GlobeNewswire - Tue Mar 18, 8:28AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISINE0005664809) will report its financial results for 2013 on Tuesday, 25 March 2014.
Eaton Vance Tax-Advantaged Dividend Income Fund Annual Meeting Of Shareholders
PR Newswire - Mon Mar 17, 2:07PM CDT
At a meeting held today, the Board of Trustees of Eaton Vance Tax-Advantaged Dividend Income Fund (the "Fund" (NYSE: EVT), a closed-end investment company, voted to hold the Annual Meeting of Shareholders of the Fund on Thursday, June 19, 2014 at 11:30 a.m. (EDT). The meeting will be held at the principal office of the Fund, Two International Place, Boston, Massachusetts 02110. Proxy materials will be mailed on or about April 28, 2014 to shareholders of record on April 10, 2014. Shareholders will be asked to vote on the election of three Class II Trustees and one Class I Trustee of the Fund.
Eaton Vance Tax-Advantaged Dividend Income Fund Report Of Earnings
PR Newswire - Fri Feb 21, 10:22AM CST
Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT), a diversified closed-end management investment company, today announced the earnings of the Fund for the three months ended November 30, 2013. The Fund's fiscal year ends on August 31, 2014.
Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: PZN, HYI, EVT
at The Street - Tue Feb 18, 9:03AM CST
PZN HYI EVT are going ex-dividend tomorrow, Wednesday, Feb. 19, 2014, 5:00 AM ET
Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz(TM) (clozapine, USP) Oral Suspension
PR Newswire - Tue Feb 11, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.
Dividend Watch: 5 Stocks Going Ex-Dividend Tomorrow: GDF, EVG, PMO, EVT, WSM
at The Street - Tue Jan 21, 9:00AM CST
GDF EVG PMO EVT WSM are going ex-dividend tomorrow, Wednesday, Jan. 22, 2014, 5:00 AM ET
Ex-Dividends To Watch: 4 Stocks Going Ex-Dividend Tomorrow: EFF, ETB, ETG, EVT
at The Street - Thu Dec 19, 9:00AM CST
EFF ETB ETG EVT are going ex-dividend tomorrow, Friday, Dec. 20, 2013, 5:00 AM ET
Eaton Vance Announces Upcoming Retirement Of Judith A. Saryan, CFA, And Changes To Eaton Vance Dividend Fund Portolio Teams
PR Newswire - Thu Nov 21, 9:07AM CST
Eaton Vance Corp. (NYSE: EV) announced today that Judith A. Saryan, CFA, Vice President of Eaton Vance Management (EVM) and a portfolio manager in EVM's equity group, will retire from the Eaton Vance organization on December 20, 2013. In connection with her retirement, the portfolio managers of the below-listed Eaton Vance dividend income funds ("Funds" are changing:
Eaton Vance Closed-End Funds Adopt Share Repurchase Programs
PR Newswire - Fri Nov 15, 3:15PM CST
The Boards of Trustees (Boards) of the below-listed Eaton Vance closed-end funds (the Funds) have authorized the repurchase by each Fund of up to 10% of its outstanding common shares as of November 11, 2013 in open-market transactions at a discount to net asset value per share (NAV).
Eaton Vance Closed-End Equity Funds Declare Monthly Distributions
PR Newswire - Fri Apr 11, 2:13PM CDT
Eaton Vance Management, the Boston-based investment adviser, announced the monthly distributions declared on the common shares of two of its closed-end equity funds (the "Funds"
. As portfolio and market conditions change, the rate of future distributions may change. The record date for the distributions is April 23, 2014, and the payable date is April 30, 2014. The ex-date is April 21, 2014. The distribution per share for each Fund is as follows: Evotec and Convergence Form Integrated Pain Alliance
GlobeNewswire - Mon Mar 31, 12:40AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain. Panion Ltd has been awarded a £ 2.4 m Technology Strategy Board Biomedical Catalyst Early Stage Round 2 grant to discover and develop compounds against a novel GPCR pain target. Evotec will be responsible for undertaking key drug discovery activities and will work closely with the Convergence team in identifying pre-clinical candidates over the next three years. Subsequently, and upon meeting certain pre-clinical milestones, Convergence and Evotec will jointly progress the assets further into the clinic or via partnering. Further financials remain undisclosed. Evotec FY 2013: Execute on Innovate to Create Value
GlobeNewswire - Tue Mar 25, 1:59AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013. Evotec AG: Fiscal Year 2013 Results Presentation on 25 March 2014
GlobeNewswire - Tue Mar 18, 8:28AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) will report its financial results for 2013 on Tuesday, 25 March 2014. Eaton Vance Tax-Advantaged Dividend Income Fund Annual Meeting Of Shareholders
PR Newswire - Mon Mar 17, 2:07PM CDT
At a meeting held today, the Board of Trustees of Eaton Vance Tax-Advantaged Dividend Income Fund (the "Fund"
(NYSE: EVT), a closed-end investment company, voted to hold the Annual Meeting of Shareholders of the Fund on Thursday, June 19, 2014 at 11:30 a.m. (EDT). The meeting will be held at the principal office of the Fund, Two International Place, Boston, Massachusetts 02110. Proxy materials will be mailed on or about April 28, 2014 to shareholders of record on April 10, 2014. Shareholders will be asked to vote on the election of three Class II Trustees and one Class I Trustee of the Fund. Eaton Vance Tax-Advantaged Dividend Income Fund Report Of Earnings
PR Newswire - Fri Feb 21, 10:22AM CST
Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT), a diversified closed-end management investment company, today announced the earnings of the Fund for the three months ended November 30, 2013. The Fund's fiscal year ends on August 31, 2014.
Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: PZN, HYI, EVT
at The Street - Tue Feb 18, 9:03AM CST
PZN HYI EVT are going ex-dividend tomorrow, Wednesday, Feb. 19, 2014, 5:00 AM ET
Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz(TM) (clozapine, USP) Oral Suspension
PR Newswire - Tue Feb 11, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.
Dividend Watch: 5 Stocks Going Ex-Dividend Tomorrow: GDF, EVG, PMO, EVT, WSM
at The Street - Tue Jan 21, 9:00AM CST
GDF EVG PMO EVT WSM are going ex-dividend tomorrow, Wednesday, Jan. 22, 2014, 5:00 AM ET
Ex-Dividends To Watch: 4 Stocks Going Ex-Dividend Tomorrow: EFF, ETB, ETG, EVT
at The Street - Thu Dec 19, 9:00AM CST
EFF ETB ETG EVT are going ex-dividend tomorrow, Friday, Dec. 20, 2013, 5:00 AM ET
Eaton Vance Announces Upcoming Retirement Of Judith A. Saryan, CFA, And Changes To Eaton Vance Dividend Fund Portolio Teams
PR Newswire - Thu Nov 21, 9:07AM CST
Eaton Vance Corp. (NYSE: EV) announced today that Judith A. Saryan, CFA, Vice President of Eaton Vance Management (EVM) and a portfolio manager in EVM's equity group, will retire from the Eaton Vance organization on December 20, 2013. In connection with her retirement, the portfolio managers of the below-listed Eaton Vance dividend income funds ("Funds"
are changing: Eaton Vance Closed-End Funds Adopt Share Repurchase Programs
PR Newswire - Fri Nov 15, 3:15PM CST
The Boards of Trustees (Boards) of the below-listed Eaton Vance closed-end funds (the Funds) have authorized the repurchase by each Fund of up to 10% of its outstanding common shares as of November 11, 2013 in open-market transactions at a discount to net asset value per share (NAV).
